VOLO · PORTFOLIO

SoFlux

SoFlux
Licence
NPN 80113974
Launched
2027

For the rapid relief of gastroesophageal reflux disease (GERD) symptoms, including heartburn, acid regurgitation, epigastric pain, and cough.

← Back to portfolio In-license with Volo →
— Also in the portfolio

Other brands we have launched and grown.

Renova

Adjunctive support for patients with chronic kidney disease (CKD) stages 1–3, specifically targeting the reduction of uremic toxin accumulation through gut microbiome modulation. Indicated to support kidney function preservation and reduce systemic inflammation associated with early-stage CKD. Mechanism of Action: A proprietary blend of targeted prebiotics and postbiotics that selectively inhibit the intestinal bacteria responsible […]

In process 2027
OptiFer 30 and 90 tablet box

OptiFer Alpha

Heme iron oral supplement. For the prevention of iron deficiency and iron deficiency anemia. OptiFer is designed for individuals who require effective iron replenishment — particularly women of reproductive age, pregnant women, and patients who have not tolerated conventional non-heme iron supplementation. The product addresses a high-prevalence clinical gap in Women’s Health and Hematology, where […]

NPN 80068954 2016
Femistina Plus and capsules

Femistina Plus

Femistina Plus provides round-the-clock defense against recurrent UTIs with its innovative triple-action mechanism. Femistina Plus is designed for use in women with a history of recurrent cystitis who are seeking a structured, non-antibiotic prophylactic strategy. It is positioned as a clinically credible adjunct or alternative to continuous low-dose antibiotic prophylaxis, aligned with global antibiotic stewardship […]

NPN 80096665 2024